Wall Street Zen Downgrades EIKN (NASDAQ:EIKN) to Sell

EIKN (NASDAQ:EIKN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages also recently commented on EIKN. Zacks Research upgraded EIKN to a “hold” rating in a report on Friday, February 27th. Wedbush reissued an “underperform” rating and set a $7.00 price objective on shares of EIKN in a research report on Tuesday, March 31st. Mizuho assumed coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $29.00 target price for the company. Finally, Bank of America began coverage on shares of EIKN in a research note on Monday, March 2nd. They set a “buy” rating and a $34.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.60.

EIKN Stock Performance

NASDAQ EIKN opened at $9.90 on Friday. EIKN has a fifty-two week low of $9.46 and a fifty-two week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.